Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first ...
Sirnaomics raised the money to advance a pipeline of drug candidates underpinned by its polypeptide nanoparticle (PNP) and GalNAc (N-Acetylgalactosamine) technology platforms (Fig. 1). PNP offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback